Tesofensine
Jump to navigation
Jump to search
| File:Tesofensine.png | |
| Gene therapy | |
|---|---|
| Clinical data | |
| Physiological data | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Identifiers | |
| |
| CAS Number | |
| Chemical and physical data | |
| Formula | C17H23Cl2NO |
| Molar mass | 328.28 g/mol |
Tesofensine is a serotonin-noradrenaline-dopamine reuptake inhibitor, which also seems to increase the action of acetylcholine in the brain, probably due to downstream effects. It was originally researched for the treatment of Alzheimer's disease and Parkinson's Disease, but was subsequently dropped from development for these applications, and is now being researched for the treatment of obesity, presumably as an appetite suppressant. As of 2006 it was in Phase II trials for the treatment of obesity.[1]
References
Categories:
- Articles with short description
- Pages with broken file links
- Drugs with non-standard legal status
- Infobox-drug molecular-weight unexpected-character
- Pages using infobox drug with unknown parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Serotonin-norepinephrine-dopamine reuptake inhibitors
- Tropanes
- Stimulants
- Sympathomimetic amines